Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2019 · 10-Q
Revenue$560.63M$560.63M+2.8% vs Q3 2018 Net Income-$258.80M-$258.80MN/M vs Q3 2018 EPS Diluted-$8.68-$8.68N/M vs Q3 2018 Gross Profit$307,000,000+7.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$99,750,000+60.2% Free Cash Flowderived$68,659,000+70.7% Margins · derivedGross margin54.8%+2.2 pt vs Q3 2018
Operating margin10.2%+3.6 pt vs Q3 2018
Net margin-46.2%−95.6 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 1, 2019 · 32 d after period end